Upadacitinib

證據等級: L5

預測適應症: 2 個

Upadacitinib: Indication Data Not Yet Available → Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

One-Sentence Summary

Upadacitinib's original approved indication and mechanism-of-action details are not yet available in this evidence pack (data gap). The TxGNN model predicts potential activity against colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare congenital developmental disorder, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal.

Quick Overview

Item	Content
Original Indication	Not available (no license/indication data on file)
Predicted New Indication	Colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	99.61% (rank 4612)
Evidence Level	L5 (model prediction only, no supporting studies)
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for upadacitinib is not currently available in this evidence pack, and no original indication is on file, so a direct mechanistic bridge cannot be constructed from the input data alone. Based on the model's own rationale output, upadacitinib is a JAK1-selective inhibitor acting on cytokine signaling (IL-6, IL-4/13, IFN pathways).

Colobomatous microphthalmia-rhizomelic dysplasia syndrome, however, is a structural/developmental disorder — congenital ocular malformation combined with proximal limb skeletal dysplasia — typically linked to ciliopathy or peroxisomal gene defects (e.g., PEX7-related rhizomelic chondrodysplasia punctata), not to inflammatory or autoimmune signaling. There is no established link between JAK-STAT cytokine signaling and the ocular/skeletal embryonic developmental pathways implicated in this syndrome.

The model's own repurposing rationale concludes that the high TxGNN score most likely reflects knowledge-graph node proximity (e.g., clustering with other rare/developmental disease nodes) rather than genuine mechanistic plausibility. No mechanistic, preclinical, or clinical evidence currently supports this pairing — this is consistent with the L5 evidence level and Hold recommendation.

A second candidate, brachydactyly-syndactyly syndrome (score 99.58%, rank 4924), shows the same pattern: a skeletal/limb-development disorder (HOX, BMP/GDF, GLI3 pathways) with no direct overlap to JAK1 inhibition, and likewise zero supporting trials or literature.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Upadacitinib is not currently marketed in Taiwan (0 authorizations on file), so no local product/authorization data is available.

Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications and MOA data are flagged as unresolved data gaps — see Conclusion below.)

Conclusion and Next Steps

Decision: Hold

Rationale: Both predicted indications are algorithm-only (L5) signals with no supporting clinical trials, literature, or plausible mechanistic link — the model's own rationale suggests the high scores likely reflect knowledge-graph proximity rather than biological relevance. The drug is also not marketed in Taiwan, and core drug-level data (MOA, TFDA label) remain unresolved.

To proceed, the following is needed:

TFDA package insert data (warnings/contraindications) — currently a Blocking data gap
Mechanism-of-action confirmation from DrugBank — currently a High-severity data gap
Original approved-indication data for upadacitinib
Preclinical or mechanistic studies directly linking JAK1 inhibition to either candidate disease before any further evaluation stage is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.